Jai Smith

Dr. Jai Smith

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Cancer Letters
Verified
Journal Article
Closed access
YQYan Qin
Yan Qin
CSCarolyn Shembrey
Carolyn Shembrey
JSJai Smith
Jai Smith
SPSophie Paquet-Fifield
Sophie Paquet-Fifield
CBCorina Behrenbruch
Corina Behrenbruch
Frederic HollandeFrederic Hollande
Frederic Hollande

25 March 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
ACAnderly Chueh
Anderly Chueh
GAGahana Advani
Gahana Advani
MFMomeneh Foroutan
Momeneh Foroutan
JSJai Smith
Jai Smith
NNNadia Ng
Nadia Ng
HCHeung Cheng
Heung Cheng

2 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GBGuillaume Belthier
Guillaume Belthier
ZHZeinab Homayed
Zeinab Homayed
FGFanny Grillet
Fanny Grillet
CDChristophe Duperray
Christophe Duperray
JVJulie A. Vendrell
Julie A. Vendrell
JPJulie Pannequin
Julie Pannequin
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches—immune detection coupled with magnetic beads and fluorescence-activated cell sorting—were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity.

24 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CSCarolyn Elizabeth Shembrey
Carolyn Elizabeth Shembrey
JSJai Smith
Jai Smith
MGMélodie Grandin
Mélodie Grandin
NWNathalia WILLIAMS
Nathalia WILLIAMS
ECEllie Cho
Ellie Cho
Frederic HollandeFrederic Hollande
Frederic Hollande
Geno- and phenotypic heterogeneity amongst cancer cell subpopulations are established drivers of treatment resistance and tumour recurrence. However, due to the technical difficulty associated with studying such intra-tumoural heterogeneity, this phenomenon is seldom interrogated in conventional cell culture models. Here, we employ a fluorescent lineage technique termed “optical barcoding” (OBC) to perform simultaneous longitudinal tracking of spatio-temporal fate in 64 patient-derived colorectal cancer subclones. To do so, patient-derived cancer cell lines and organoids were labelled with discrete combinations of reporter constructs, stably integrated into the genome and thus passed on from the founder cell to all its clonal descendants. This strategy enables the longitudinal monitoring of individual cell lineages based upon their unique optical barcodes. By designing a novel panel of six fluorescent proteins, the maximum theoretical subpopulation resolution of 64 discriminable subpopulations was achieved, greatly improving throughput compared with previous studies. We demonstrate that all subpopulations can be purified from complex clonal mixtures via flow cytometry, permitting the downstream isolation and analysis of any lineages of interest. Moreover, we outline an optimized imaging protocol that can be used to image optical barcodes in real-time, allowing for clonal dynamics to be resolved in live cells. In contrast with the limited intra-tumour heterogeneity observed in conventional 2D cell lines, the OBC technique was successfully used to quantify dynamic clonal expansions and contractions in 3D patient-derived organoids, which were previously demonstrated to better recapitulate the heterogeneity of their parental tumour material. In summary, we present OBC as a user-friendly, inexpensive, and high-throughput technique for monitoring intra-tumoural heterogeneity in in vitro cell culture models.